For research use only. Not for therapeutic Use.
Tasosartan is an angiotensin II receptor antagonist.
| Catalog Number | R063330 |
| CAS Number | 145733-36-4 |
| Synonyms | 5,8-Dihydro-2,4-dimethyl-8-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one;?5,8-Dihydro-2,4-dimethyl-8-[[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one; Verdia; WAY-ANA 756 |
| Molecular Formula | C23H21N7O |
| Purity | ≥95% |
| Target | Angiotensin Receptor |
| Storage | 3 years -20C powder |
| IUPAC Name | 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one |
| InChI | InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29) |
| InChIKey | ADXGNEYLLLSOAR-UHFFFAOYSA-N |
| SMILES | CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5 |
| Reference | </br>1:Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. Elokdah HM, Friedrichs GS, Chai SY, Harrison BL, Primeau J, Chlenov M, Crandall DL.Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71. PMID: 12113820 </br>2:Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. Maillard MP, Rossat J, Brunner HR, Burnier M.J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. PMID: 11046101 Free Article</br>3:Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: comparison with enalapril. Tasosartan Study Group. Viigimaa M, Allikmets K, Parik T, Skards J, Franken A, Häss G.Cardiovasc Drugs Ther. 2000 Aug;14(4):447-9. No abstract available. PMID: 10999653 </br>4:A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. Andrawis NS, Battle MM, Klamerus KJ, Burghart PH, Neefe L, Weinryb I, Mayer P, Abernethy DR.J Clin Pharmacol. 2000 Mar;40(3):231-41. PMID: 10709151 </br>5:Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. Rhéaume C, Waib PH, Lacourcière Y, Cléroux J.J Hypertens. 1998 Dec;16(12 Pt 2):2085-9. PMID: 9886901 </br>6:Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group. Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M.Am Heart J. 1999 Jan;137(1):118-25. PMID: 9878944 </br>7:Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group. Ellingboe JW, Collini MD, Quagliato D, Chen J, Antane M, Schmid J, Hartupee D, White V, Park CH, Tanikella T, Bagli JF.J Med Chem. 1998 Oct 22;41(22):4251-60. PMID: 9784100 </br>8:A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator/’s Group. Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Larochelle P, de Champlain J, Smith WB.Am J Hypertens. 1998 Apr;11(4 Pt 1):454-61. PMID: 9607384 |
